AI-generated analysis. Always verify with the original filing.
KalVista Pharmaceuticals reported financial results for the eight-month transition period ended December 31, 2025, including $49.1 million global net product revenue from EKTERLY and cash, cash equivalents and marketable securities of $300.2 million. Updates highlighted rapid US adoption with 1,702 patient start forms through February 2026 and EKTERLY launch in Japan.
Event Type
Disclosure
Mandatory
Variant
8-K
of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated March 25, 2026 104 Cover Page Interactive Data File
| Metric | Value | Basis |
|---|---|---|
| Product revenue, net | $49.10 | GAAP |
| Cost of revenue | $3.10 | GAAP |
| Research and development expenses | $33.40 | GAAP |
| Selling, general and administrative expenses | $124.70 | GAAP |
| Operating loss | $-112.00 | GAAP |
| Net loss | $-109.50 | GAAP |
| Net loss per share, basic and diluted | $-2.03 | GAAP |